Citius Pharmaceuticals, Inc. has appointed Mr. Holubiak to the newly created position of Executive Vice Chairman with responsibility for building the Citius commercial team and guiding the anticipated product launches of the Company's first commercial products. Mr. Holubiak will drive the overall commercial strategy in support of the Citius pipeline. The near-term focus will be on the successful launch of I/ONTAK for the systemic treatment of cutaneous T-cell lymphoma (CTCL), which recently released topline results from its Phase 3 trial, and Mino-Lok which is expected to complete Phase 3 trial enrollment later this year.

Leonard Mazur, Citius co-founder and Executive Chairman has been named as CEO and Chairman by the Board of Directors. Additionally, in recognition of the incremental needs of a growing Citius team, Chief Financial Officer Jaime Bartushak will assume additional responsibilities as Chief Business Officer. Co-founder, Myron Holubiak to transition from President & CEO to Executive Vice Chairman of the Board of Directors to build commercial capabilities, effective May 1, 2022.

Mr. Holubiak is uniquely experienced to drive the commercialization strategy for Citius. While President of Roche Laboratories, he led the organization in successfully launching important oncology and antibiotic products including Xeloda® for the treatment of breast and colorectal cancer, and Rocephin®, the most successful injectable cephalosporin antibiotic at the time. Jamie Bartushak, Citius' Chief Financial Officer, will assume additional operational responsibilities in his expanded role as Chief Business Officer.

He will oversee all aspects of finance, business development and operations at the Company. In order to efficiently bring the Company's products to market, Michael McGuire will join Citius as VP, Program Leader for Anti-Infectives effective May 1, 2022. Mr. McGuire will work closely with Mr. Holubiak and the rest of the Citius team to leverage his broad pharmaceutical experience and network.

About Michael McGuire, VP, Program Leader for Anti-Infectives: Michael McGuire has extensive business leadership experience within the pharmaceutical industry, including P&L management, strategic planning, marketing, and new product development. While at Roche Laboratories, Michael led the Tamiflu franchise to become the first billion-dollar product for Roche in the United States, and designed an award-winning direct-to-consumer (DTC) Tamiflu educational campaign that raised consumer awareness by 65%. Most recently, Mr. McGuire was Senior Vice President Commercial, Government Affairs, and Customer Engagement at Melinta Therapeutics.

In this role, he called on members of the House and Senate and met with representatives from the Centers for Medicare and Medicaid Services (CMS) and the Biomedical Advanced Research and Development Authority (BARDA) to develop support for the DISARM Act that would change the reimbursement landscape for anti-infectives. Additionally, he integrated three commercial organizations (Melinta, Cempra, and The Medicines Company) while launching two new anti-infective drugs. Prior to joining Melinta, Michael served as Senior Vice President, Global Infectious Disease at The Medicines Company, a developer of hospital products in the anti-infective and cardiovascular therapeutic areas.

He managed global commercial operations for an anti-infective portfolio of products, and successfully launched the drug Orbactiv in a highly competitive generic and branded marketplace. As a seasoned executive, Mr. McGuire has successfully launched multiple anti-infective products, including a blockbuster drug, built alliances with government agencies, launched consumer awareness programs, and effectively managed commercial organization costs.